Are Myeloproliferative Neoplasms a Rare Disease?

MPNs are not a rare disease

by David Wallace Let’s Define the term “Rare Disease” Now that all of the hoopla of “Rare Disease Day” has passed, it is time to peel away the layers of misconception, myths and false belief to uncover the truth.  First of all, let’s define the term “rare disease.”  In the United States, a rare disease […]

Final of 3 MPN Patient Surveys

MPN Survey

Update on Upcoming MPN surveys Dear MPN Community, We are currently in an unprecedented time regarding greater understanding of myeloproliferative neoplasms (MPNs). The testing of new therapeutic agents and a genuine effort to improve the education of providers and patients will help increase options and achieve better patient outcomes. This spring of 2014, three different […]

MPD-RC 111 Clinical Trial for High Risk Polycythemia Vera or Essential Thrombocythemia

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]

MPD-RC 112 Clinical Trial for High Risk PV and ET Patients

Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points:  Why are we doing the Study? Top […]

Emerging Drugs for Polycythemia Vera

pegasys MPN

Polycythem Vera – Expert Opinion on Emerging Drugs Raoul Tibes, Ruben A Mesa Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology & Medical Oncology , 13400 E. Shea Boulevard, Scottsdale, AZ 85259 , USA +1 480 301 6740 ; +1 480 301 4675 ; . Expert Opinion on Emerging Drugs (Impact Factor: […]

error: Content is protected !
Malcare WordPress Security